Just super smart by management to go aggressive on pre clinical in applications that will allow it to fast track as orphan drug. Tipping they might even apply for fast track here as well - again not telling the market this is happening.
Once the heavy lifting is done in phase trials for 2591- it will become much easier to begin exploring other autism spectrum disorders.
I would be pretty comfortable in saying they have been doing this kind of work on several indications and PMS has come out as the most benefit gained from 2591. With the end market only being around 1,200 patients - this would never make commercial sense to go after from the outset.
I believe management have done this with the sole purpose to pick the condition they are most confident in showing benefit in the shortest time. Three month trial again!.
Orphan & Fast track!
They could go the whole way themselves, however I'm tipping that they will partner again, but this time it will be blue chip pharma (could be ACADIA by then), but will be for blue chip $upfront and royalties.
All very exciting - Cant believe we're this close to the goals and at this price still.
Heaven forbid its still at the price come tax return time.
NEU Price at posting:
$1.12 Sentiment: Buy Disclosure: Held
A personalised tool to help users track selected stocks. Delivering real-time notifications on price updates, announcements, and performance stats on each to help make informed investment decisions.
(20min delay)